35703-53-8

Usage

Type of compound

Nitrile derivative

Structure

Contains a phenyl ring with a chlorine and a methyl group attached

Potential applications

Organic synthesis, production of pharmaceuticals and agrochemicals

Research interests

Development of new materials and catalysts

Toxicological properties

May have some toxicological properties, requiring precautions during handling and usage

Upstream product

• 773837-37-9 sodium cyanide 
• 55676-89-6 2-methyl-3-chlorobenzyl chloride 
• 90369-76-9 1-(bromomethyl)-3-chloro-2-methyl benzene 

Downstream Products

• 1118761-73-1 C₁₄H₉BrClNO 

Relevant academic research and scientific papers

HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

Rational modification of a candidate cancer drug for use against chagas disease

Chagas disease is one of the major neglected diseases of the world. Existing drug therapies are limited, ineffective, and highly toxic. We describe a novel strategy of drug discovery of adapting an existing clinical compound with excellent pharmaceutical properties to target a pathogenic organism. The protein farnesyltransferase (PFT) inhibitor tipifarnib, now in phase III anticancer clinical trials, was previously found to kill Trypanosoma cruzi by blocking sterol 14a-demethylase (14DM). We rationally developed tipifarnib analogues that display reduced affinity for human PFT to reduce toxicity while increasing affinity for parasite 14DM. The lead compound has picomolar activity against cultured T. cruzi and is efficacious in a mouse model of acute Chagas disease.